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Abstract: Pathway analysis has become the first choice
for gaining insight into the underlying biology of
differentially expressed genes and proteins, as it reduces
complexity and has increased explanatory power. We
discuss the evolution of knowledge base–driven pathway
analysis over its first decade, distinctly divided into three
generations. We also discuss the limitations that are
specific to each generation, and how they are addressed
by successive generations of methods. We identify a
number of annotation challenges that must be addressed
to enable development of the next generation of pathway
analysis methods. Furthermore, we identify a number of
methodological challenges that the next generation of
methods must tackle to take advantage of the techno-
logical advances in genomics and proteomics in order to
improve specificity, sensitivity, and relevance of pathway
analysis.
Introduction
Techniques such as high-throughput sequencing and gene/
protein profiling techniques have transformed biological research
by enabling comprehensive monitoring of a biological system.
Irrespective of the technology used, analysis of high-throughput
data typically yields a list of differentially expressed genes or
proteins. This list is extremely useful in identifying genes that may
have roles in a given phenomenon or phenotype. However, for
many investigators, this list often fails to provide mechanistic
insights into the underlying biology of the condition being studied.
In this way, the advent of high-throughput profiling technologies
presents a new challenge, that of extracting meaning from a long
list of differentially expressed genes and proteins.
One approach to this challenge has been to simplify analysis by
grouping long lists of individual genes into smaller sets of related
genes or proteins. This approach reduces the complexity of
analysis. Researchers have developed a large number of
knowledge bases to help with this task. The knowledge bases
describe biological processes, components, or structures in which
individual genes and proteins are known to be involved in, as well
as how and where gene products interact with each other. One
example of this idea is to identify groups of genes that function in
the same pathways.
Analyzing high-throughput molecular measurements at the
functional level is very appealing for two reasons. First, grouping
thousands of genes, proteins, and/or other biological molecules by
the pathways they are involved in reduces the complexity to just
several hundred pathways for the experiment. Second, identifying
active pathways that differ between two conditions can have more
explanatory power than a simple list of different genes or proteins
[1].
The goals of this review are to i) describe the existing knowledge
base–driven pathway analysis methods, ii) discuss limitations of
each class of methods, and iii) describe the challenges not yet
addressed by any method.
Existing Pathway Analytic Approaches
The term ‘‘pathway analysis’’ has been used in very broad
contexts in the literature [2]. It has been applied to the analysis of
Gene Ontology (GO) terms (also referred to as a ‘‘gene set’’),
physical interaction networks (e.g., protein–protein interactions),
kinetic simulation of pathways, steady-state pathway analysis (e.g.,
flux-balance analysis), and in the inference of pathways from
expression and sequence data. However, the definition of a
‘‘pathway’’ in some of these uses may be misleading or incorrect.
For instance, the cellular compartment ontology in GO does not
describe a pathway.
It is beyond the scope of this review to discuss the large number
of analytic methods covered by such a broad application of the
term ‘‘pathway analysis.’’ Therefore, this review focuses on
methods that exploit pathway knowledge in public repositories
such as GO or Kyoto Encyclopedia of Genes and Genomes
(KEGG), rather than on methods that infer pathways from
molecular measurements. We call this approach knowledge base–
driven pathway analysis. It identifies pathways that may be affected
in a condition by correlating information in at least one pathway
knowledge base with gene expression patterns for the condition.
The result is differential expression of a set of genes or proteins
rather than a list of individual genes.
Instead of individually reviewing a large number of pathway
analysis approaches, our goal here is to group approaches by the
type of analysis they perform and discuss their relative merits.
However, for those desiring specific information about individual
tools, Text S2 provides feature comparisons for a number of
individual tools in each group.
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,Virtually all of the approaches and tools discussed here are
independent of the data generated from most high-throughput
technologies, including next-generation sequencing data and the
knowledge bases used for pathway annotations. In this review, we
use gene expression measurements as example data for discussing
and explaining various approaches.
First Generation: Over-Representation Analysis (ORA)
Approaches
The immediate need for functional analysis of microarray gene
expression data and the emergence of GO during that period gave
rise to over-representation analysis (ORA), which statistically
evaluates the fraction of genes in a particular pathway found
among the set of genes showing changes in expression (Table 1). It
is also referred to as ‘‘262 table method’’ in the literature [3].
ORA uses one or more variations of the following strategy [4–11]
(Figure 1): first, an input list is created using a certain threshold or
criteria. For example, a researcher may choose genes that are
differentially over- or under-expressed in a given condition at a
false discovery rate (FDR) of 5%. Then, for each pathway, input
genes that are part of the pathway are counted. This process is
repeated for an appropriate background list of genes (e.g., all genes
measured on a microarray). Next, every pathway is tested for over-
or under-representation in the list of input genes. The most
commonly used tests are based on the hypergeometric, chi-square,
or binomial distribution. We refer the readers to recent
comparisons of ORA tools for more details [12,13]. Many of the
ORA tools differ very slightly from each other as they use the same
Table 1. Examples of pathway analysis tools in each generation.
Name Availability Reference
ORA tools
Onto-Express Web (http://vortex.cs.wayne.edu) [4,5]
GenMAPP Standalone (http://www.genmapp.org) [11,71]
GoMiner Standalone, Web (http://discover.nci.nih.gov/gominer) [72,73]
FatiGO Web (http://babelomics.bioinfo.cipf.es) [74]
GOstat Web (http://gostat.wehi.edu.au) [7]
FuncAssociate Web (http://llama.mshri.on.ca/funcassociate/) [6]
GOToolBox Web (http://genome.crg.es/GOToolBox/) [10]
GeneMerge Standalone, Web (http://genemerge.cbcb.umd.edu/) [9]
GOEAST Web (http://omicslab.genetics.ac.cn/GOEAST/) [75]
ClueGO Standalone (http://www.ici.upmc.fr/cluego/) [76]
FunSpec Web (http://funspec.med.utoronto.ca/) [77]
GARBAN Web [78]
GO:TermFinder Standalone (http://search.cpan.org/dist/GO-TermFinder/) [8]
WebGestalt Web (http://bioinfo.vanderbilt.edu/webgestalt/) [79]
agriGO Web (http://bioinfo.cau.edu.cn/agriGO/) [80]
GOFFA Standalone, Web (http://edkb.fda.gov/webstart/arraytrack/) [81]
WEGO Web (http://wego.genomics.org.cn/cgi-bin/wego/index.pl) [82]
FCS tools
GSEA Standalone (http://www.broadinstitute.org/gsea/) [21,29]
sigPathway Standalone (BioConductor) [22]
Category Standalone (BioConductor) [24]
SAFE Standalone (BioConductor) [30]
GlobalTest Standalone (BioConductor) [15]
PCOT2 Standalone (BioConductor) [17]
SAM-GS Standalone (http://www.ualberta.ca/,yyasui/software.html) [83]
Catmap Standalone (http://bioinfo.thep.lu.se/catmap.html) [84]
T-profiler Web (http://www.t-profiler.org) [85]
FunCluster Standalone (http://corneliu.henegar.info/FunCluster.htm) [86]
GeneTrail Web (http://genetrail.bioinf.uni-sb.de) [87]
GAzer Web [88]
PT-based tools
ScorePAGE No implementation available [37]
Pathway-Express Web (http://vortex.cs.wayne.edu) [38,39]
SPIA Standalone (BioConductor) [40]
NetGSA No implementation available [43]
doi:10.1371/journal.pcbi.1002375.t001
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Limitations. Despite the availability of a large number of tools
andtheirwidespread usage, ORA hasa numberoflimitations.First,
the different statistics used by ORA (e.g., hypergeometric
distribution, binomial distribution, chi-square distribution, etc.)
are independent of the measured changes. This means that these
tests consider the number of genes alone and ignore any values
associated with them such as probe intensities. By discarding this
data, ORA treats each gene equally. However, the information
about the extent of regulation (e.g., fold-changes, significance of a
change, etc.) can be useful in assigning different weights to input
genes, as well as to the pathways they are involved in, which in turn
can provide more information than current ORA approaches.
Second, ORA typically uses only the most significant genes and
discards the others. For instance, the input list of genes from a
microarray experiment is usually obtained using an arbitrary
threshold (e.g., genes with fold-change §2 and/or p-valuesƒ0:05).
With this method, marginally less significant genes (e.g., fold-
change=1.999 or p-value=0.051) are missed, resulting in infor-
mation loss. Breitling et al. addressed this problem by proposing an
ORA method for avoiding thresholds. It uses an iterative approach
that adds one gene at a time to find a set of genes for which a
pathway is most significant [14].
Third, by treating each gene equally, ORA assumes that each
gene is independent of the other genes. However, biology is a
complex web of interactions between gene products that constitute
different pathways. One goal of gene expression analysis might be to
gain insights into how interactions between gene products are
manifested as changes in gene expression. A strategy that assumes
the genes are independent is significantly limited in its ability to
provide insightsinthisregard.Furthermore,assumingindependence
between genes amounts to ‘‘competitive null hypothesis’’ testing (see
below), which ignores the correlation structure between genes.
Consequently,theestimatedsignificanceofapathwaymaybebiased
or incorrect.
Fourth, ORA assumes that each pathway is independent of other
pathways, which is erroneous. For instance, GO defines a biological
process as a series of events accomplished by one or more ordered
assemblies of molecular functions (http://www.geneontology.org/
GO.doc.shtml). Another example of dependence between pathways
is the cell cycle pathway in KEGG (http://www.genome.jp/kegg/
pathway/hsa/hsa04110.html), where the presence of a growth
factor activates the MAPK signaling pathway. This, in turn,
activates the cell cycle pathway. No ORA methods account for this
dependence between molecular functions in GO and signaling
pathways in KEGG.
Second Generation: Functional Class Scoring (FCS)
Approaches
The hypothesis of functional class scoring (FCS) is that although
large changes in individual genes can have significant effects on
pathways, weaker but coordinated changes in sets of functionally
related genes (i.e., pathways) can also have significant effects. With
few exceptions [15–17], all FCS methods use a variation of a
general framework that consists of the following three steps [18]
(Figure 1; Table 1): first, a gene-level statistic is computed using the
molecular measurements from an experiment. This involves
computing differential expression of individual genes or proteins.
Statistics currently used at gene-level include correlation of
molecular measurements with phenotype [19], ANOVA [20],
Q-statistic [15], signal-to-noise ratio [21], t-test [20,22], and Z-
score [23]. Although the choice of a gene-level statistic has a
Figure 1. Overview of existing pathway analysis methods using gene expression data as an example. Note that this overview is equally
applicable to molecular measurements using proteomics, and any other high-throughput technologies. The data generated by an experiment using a
high-throughput technology (e.g., microarray, proteomics, metabolomics), along with functional annotations (pathway database) of the
corresponding genome, are input to virtually all pathway analysis methods. While ORA methods require that the input is a list of differentially
expressed genes, FCS methods use the entire data matrix as input. In addition to functional annotations of a genome, PT-based methods utilize the
number and type of interactions between gene products, which may or may not be a part of a pathway database. The result of every pathway
analysis method is a list of significant pathways in the condition under study. DE, differentially expressed.
doi:10.1371/journal.pcbi.1002375.g001
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sets [18], when there are few biological replicates, a regularized
statistic may be better. Furthermore, untransformed gene-level
statistics can fail to identify pathways with up- and down-regulated
genes. In this case, transformation of gene-level statistics (e.g.,
absolute values, squared values, ranks, etc.) is preferable [18,24].
Second, the gene-level statistics for all genes in a pathway are
aggregated into a single pathway-level statistic. This statistic can be
multivariate [17,25–28] and account for interdependencies among
genes, or it can be univariate [22,24] and disregard interdepen-
dencies among genes. The pathway-level statistics used by current
approaches include the Kolmogorov-Smirnov statistic [21,29],
sum, mean, or median of gene-level statistic [24], the Wilcoxon
rank sum [30], and the maxmean statistic [31]. Irrespective of its
type, the power of a pathway-level statistic can depend on the
proportion of differentially expressed genes in a pathway, the size
of the pathway, and the amount of correlation between genes in
the pathway. Interestingly, although multivariate statistics are
expected to have higher statistical power, univariate statistics show
more power at stringent cutoffs when applied to real biological
data (pƒ0:001), and equal power as multivariate statistics at less
stringent cutoffs (pƒ0:05) [1].
The final step in FCS is assessing the statistical significance of
the pathway-level statistic. When computing statistical signifi-
cance, the null hypothesis tested by current pathway analysis
approaches can be broadly divided into two categories: i)
competitive null hypothesis and ii) self-contained null hypothesis
[3,18,22,31]. A self-contained null hypothesis permutes class labels
(i.e., phenotypes) for each sample and compares the set of genes in
a given pathway with itself, while ignoring the genes that are not in
the pathway. On the other hand, a competitive null hypothesis
permutes gene labels for each pathway, and compares the set of
genes in the pathway with a set of genes that are not in the
pathway. Text S2 has a detailed discussion on the differences
between the two null hypotheses.
FCS methods address three limitations of ORA. First, they do
not require an arbitrary threshold for dividing expression data into
significant and non-significant pools. Rather, FCS methods use all
available molecular measurements for pathway analysis. Second,
while ORA completely ignores molecular measurements when
identifying significant pathways, FCS methods use this information
in order to detect coordinated changes in the expression of genes
in the same pathway. Finally, by considering the coordinated
changes in gene expression, FCS methods account for dependence
between genes in a pathway, which ORA does not.
Limitations. Although FCS is an improvement over ORA
[19,22], it also has several limitations. First, similar to ORA, FCS
analyzes each pathway independently. This is a limitation because
a gene can function in more than one pathway, meaning that
pathways can cross and overlap. Consequently, in an experiment,
while one pathway may be affected in an experiment, one may
observe other pathways being significantly affected due to the set
of overlapping genes. Such a phenomenon is very common when
using the GO terms to define pathways due to the hierarchical
nature of the GO.
Second, many FCS methods use changes in gene expression to
rank genes in a given pathway, and discard the changes from
further analysis. For instance, assume that two genes in a pathway,
A and B, are changing by 2-fold and 20-fold, respectively. As long
as they both have the same respective ranks in comparison with
other genes in the pathway, most FCS methods will treat them
equally, although the gene with the higher fold-change should
probably get more weight. Importantly, however, considering only
the ranks of genes is also advantageous, as it is more robust to
outliers. A notable exception to this scenario is approaches that use
gene-level statistics (e.g., t-statistic) to compute pathway-level
scores. For example, an FCS method that computes a pathway-
level statistic as a sum or mean of the gene-level statistic accounts
for a relative difference in measurements (e.g., Category, SAFE in
Table S2).
Third Generation: Pathway Topology (PT)-Based
Approaches
A large number of publicly available pathway knowledge bases
provide information beyond simple lists of genes for each pathway.
Unlike GO and the Molecular Signatures Database (MSigDB),
these knowledge bases also provide information about gene
products that interact with each other in a given pathway, how
they interact (e.g., activation, inhibition, etc.), and where they
interact (e.g., cytoplasm, nucleus, etc.). These knowledge bases
include KEGG [32], MetaCyc [33], Reactome [34], RegulonDB
[35], STKE (http://stke.sciencemag.org), BioCarta (http://www.
biocarta.com), and PantherDB [36].
ORA and FCS methods consider only the number of genes in a
pathway or gene coexpression to identify significant pathways, and
ignore the additional information available from these knowledge
bases. Hence, even if the pathways are completely redrawn with
new links between the genes, as long as they contain the same set
of genes, ORA and FCS will produce the same results. Pathway
topology (PT)-based methods (Table 1; Table S3) have been
developed to utilize the additional information. PT-based methods
are essentially the same as FCS methods in that they perform the
same three steps as FCS methods. The key difference between the
two is the use of pathway topology to compute gene-level statistics.
Rahnenfuhrer et al. proposed ScorePAGE, which computes
similarity between each pair of genes in a pathway (e.g.,
correlation, covariance, etc.) [37]. The similarity measurement
between each pair of genes is analogous to gene-level statistics in
FCS methods, which is averaged to compute a pathway-level
score. However, instead of giving equal weight to all pairwise
similarities, ScorePAGE divides the pairwise similarities by the
number of reactions needed to connect two genes in a given
pathway (Figure 1). Although the approach is designed to analyze
metabolic pathways, it is theoretically also applicable to signaling
pathways.
A recent impact factor (IF) analytic approach was proposed to
analyze signaling pathways. IF considers the structure and
dynamics of an entire pathway by incorporating a number of
important biological factors, including changes in gene expression,
types of interactions, and the positions of genes in a pathway
[38,39] (Figure 1). Briefly, IF analysis models a signaling pathway
as a graph, where nodes represent genes and edges represent
interactions between them. Further, it defines a gene-level statistic,
called perturbation factor (PF) of a gene, as a sum of its measured
change in expression and a linear function of the perturbation
factors of all genes in a pathway (see Equation 1 in Text S1).
Because the PF of each gene is defined by a linear equation, the
entire pathway is defined as a linear system. Representing a
pathway as a linear system also addresses loops in the pathways
[39]. The IF of a pathway (pathway-level statistic) is defined as a
sum of PF of all genes in a pathway (see Equation 2 in Text S1). IF
analysis was recently improved to address the dominating effect of
change in expression on PF and high false positive rate for a small
list of input genes [40].
FCS methods that use correlations among genes [19,41]
implicitly assume that the underlying network, as defined by the
correlation structure, does not change as the experimental
conditions change. However, this assumption may be inaccurate.
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genes in the urea-cycle pathway changes with a change in
expression of ARG2 [42], suggesting changes in the topology of the
pathway.
Shojaie et al. proposed a method, called NetGSA, that accounts
for the the change in correlation as well as the change in network
structure as experimental conditions change [43]. Their approach,
like IF analysis, models gene expression as a linear function of
other genes in the network. However, it differs from IF in two
aspects. First, it accounts for a gene’s baseline expression by
representing it as a latent variable in the model. Second, it requires
that the pathways be represented as directed acyclic graphs
(DAGs). If a pathway contains cycles, NetGSA requires additional
latent variables affecting the nodes in the cycle. In contrast, IF
analysis does not impose any constraint on the structure of a
pathway [39].
Limitations. Although PT-based methods are difficult to
generalize, they have several common limitations. One obvious
problem is that true pathway topology is dependent on the type of
cell due to cell-specific gene expression profiles and condition
being studied. However, this information is rarely available and is
fragmented in knowledge bases, even if it is fully understood [44].
As annotations improve, these approaches are expected to become
more useful. Other limitations of PT-based methods include the
inability to model dynamic states of a system and the inability to
consider interactions between pathways due to weak inter-
pathway links to account for interdependence between pathways.
These limitations are discussed in detail in the Outstanding
Challenges section below.
Outstanding Challenges in Pathway Analysis
The current challenges in pathway analysis can be divided into
two broad categories: i) annotation challenges and ii) methodo-
logical challenges. We believe that development of the next
generation of pathway analytic approaches will require improve-
ment of the existing annotations. It is necessary to create accurate,
high resolution knowledge bases with detailed condition-, tissue-,
and cell-specific functions of each gene. These knowledge bases
will allow investigators to model an organism’s biology as a
dynamic system, and will help predict changes in the system due to
factors such as mutations or environmental changes.
Annotation Challenges
Low resolution knowledge bases. Recent technological
advances in genomics and proteomics are generating data at
unprecedented high resolution. As a result, there is a need for
correspondingly high resolution annotation knowledge bases. For
instance, using RNA-seq, more than 90% of the human genome is
estimated to be alternatively spliced. Multiple transcripts from the
same gene may have related, distinct, or even opposing functions
[45]. Similarly, genome-wide association studies (GWASs) have
identified a large number of SNPs that may be involved in
different conditions and diseases. However, current knowledge
bases only specify which genes are active in a given pathway. It is
essential that they also begin specifying other information, such as
transcripts that are active in a given pathway or how a given SNP
affects a pathway (Figure 2). To the best of our knowledge, because
of these low resolution knowledge bases, every available pathway
analysis tool first maps the input to a non-redundant namespace,
typically an Entrez Gene ID [46]. Arguably, this type of mapping
is advantageous [47], although it can be non-trivial [48] and
dynamic [49], as it allows the existing pathway analysis
approaches to be independent of the technology used in the
experiment. However, mapping in this way also results in the loss
of important information that may have been provided because a
specific technology was used. For instance, XRN2a, a variant of
gene XRN2, is expressed in several human tissues, whereas another
variant of the same gene, XRN2b, is mainly expressed in blood
leukocytes [50]. Although RNA-seq can quantify expression of
both variants, mapping both transcripts to a single gene causes loss
of tissue-specific information, and possibly even condition-specific
information.
Therefore, before pathway analysis can exploit current and
future technological advances in biotechnology, it is critically
important to annotate exact transcripts and SNPs that participate
in a given pathway. While new approaches are being developed in
this regard, they may not yet be adequate. For example, Braun et
al. proposed a method for analyzing SNP data from a GWAS [51].
However, this approach still relies on mapping multiple SNPs to a
single gene, followed by gene-to-pathway mapping [51]. Hence,
the limited applicability of today’s knowledge bases to emerging
technologies shows the need for increased resolution of knowledge
bases.
Incomplete and inaccurate annotations. Despite the
enormous number of annotations available in the public
domain, a surprisingly large number of genes are still not
annotated. For instance, the November 2009 release of GO
contained entries for 18,587 human genes annotated with at least
one GO term (Figure 3). Many of the genes are hypothetical,
predicted, or pseudogenes. For example, although the number of
protein-coding genes in the human genome is estimated to be
between 20,000 and 25,000 [52], according to National Center for
Biotechnology Information (NCBI) Entrez Gene, there are 45,283
human genes, of which 14,162 are pseudogenes (Table S4). One
could argue that the pseudogenes should not be included when
evaluating functional annotation coverage. However, pseudogene-
derived small interfering RNAs have been shown to regulate gene
expression in mouse oocytes [53]. Furthermore, GO provides
annotations for 271 pseudogenes. A widely used DNA microarray,
Affymetrix HG U133 plus 2.0, contains 1,026 probe sets that
correspond to 823 pseudogenes. Based on these examples, we
believe that the pseudogenes should be included in the count when
estimating annotation coverage for the human genome.
In addition to incomplete annotations, many of the existing
annotations are of low quality and may be inaccurate. For
instance, .95% of the annotations in the October 2007 release of
GO had the evidence code ‘‘inferred from electronic annotations
(IEA)’’. These annotations are the only ones in GO that are not
curated manually [54]. Annotations inferred from indirect
evidence are considered to be of lower quality than those derived
from direct experimental evidence, although this opinion has not
been shown robustly [54]. If the annotations with IEA code are
removed, the number of genes with good quality annotations in
the November 2009 release of human GO annotations is reduced
from 18,587 to 11,890 (Figure 3).
It is very likely that the reduced number of annotations and
annotated genes since January 2003 is an indicator of improving
quality. This is due in part to the fact that the number of genes in a
genome are continuously being adjusted and the functional
annotation algorithms are being improved. Indeed, the number
of non-IEA annotations is continuously increasing (Figure 3).
However, the rate of increase for non-IEA annotations is very slow
(approximately 2,000 genes annotated in 7 years; Figure 3).
Manual curation of the entire genome is expected to take a very
long time (,13–25 years) [55]. In order to exponentially increase
coverage, resolution, and accuracy of annotations, we believe that
the entire research community must participate in the curation
PLoS Computational Biology | www.ploscompbiol.org 5 February 2012 | Volume 8 | Issue 2 | e1002375Figure 2. Overview of low resolution, missing, and incomplete information. Green arrows represent abundantly available information, and
red arrows represent missing and/or incomplete information. The ultimate goal of pathway analysis is to analyze a biological system as a large, single
network. However, the links between smaller individual pathways are not yet well known. Furthermore, the effects of a SNP on a given pathway are
also missing from current knowledge bases. While some pathways are known to be related to a few diseases, it is not clear whether the changes in
pathways are the cause for those diseases or the downstream effects of the diseases.
doi:10.1371/journal.pcbi.1002375.g002
Figure 3. Number of GO-annotated genes (left panel) and number of GO annotations (right panel) for human from January 2003 to
November 2009. As the estimated number of known genes in the human genome is adjusted (between January 2003 and December 2003) and
annotation practices are modified (between December 2004 and December 2005, and between October 2008 and November 2009), one can argue
that, although the number of annotated genes and the annotations are decreasing (which is mainly due to the adjusted number of genes in the
human genome and changes in the annotation process), the quality of annotations is improving, as demonstrated by the steady increase in non-IEA
annotations and the number of genes with non-IEA annotations. However, the increase in the number of genes with non-IEA annotations is very
slow. In almost 7 years, between January 2003 and November 2009, only 2,039 new genes received non-IEA annotations. At the same time, the
number of non-IEA annotations increased from 35,925 to 65,741, indicating a strong research bias for a small number of genes.
doi:10.1371/journal.pcbi.1002375.g003
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of researchers is to adopt a standard annotation format similar to
Minimum Information About a Microarray Experiment (MIAME)
[56]. The majority of journals now require that data from DNA
microarray experiments and other high-throughput experiments
be deposited in MIAME-compliant format prior to publication.
Since its introduction in 2002, the Gene Expression Omnibus
(GEO) [57] database at NCBI has collected 637,643 samples from
25,783 experiments on 9,385 platforms (data current as of
October 2011). Similarly, it may also be beneficial to require
deposition of functional study data in standard format in public
repositories. A format for functional annotation can be designed or
adopted from the existing formats (e.g., BioPAX, SBML). Such a
format can allow researchers to specify an experimentally
confirmed role of a specific transcript or a SNP in a pathway
along with experimental and biological conditions. Such a
repository would improve the state of functional annotations in
public domains, and also enable development of the next
generation of large-scale pathway analysis tools.
Missing condition- and cell-specific information. Most
pathway knowledge bases are built by curating experiments
performed in different cell types at different time points under
different conditions. However, these details are typically not available
in the knowledge bases. One effect of this omission is that multiple
independent genes are annotated to participate in the same
interaction in a pathway. This effect is so widespread that many
pathway knowledge bases represent a set of distinct genes as a single
node in a pathway, and is part of the standard BioPAX format.
An example of this problem is the Wnt/beta-catenin pathway in
STKE (http://stke.sciencemag.org/cgi/cm/stkecm;CMC_6032; free
registration is required to view this website), where the node labeled
‘‘Genes’’ represents 19 genes directly targeted by Wnt in different
organisms (Xenopus [58] and human [59]) in different cells and tissues
(colon carcinoma cells [60] and epithelial cells [61]). These non-specific
genes introduce bias for these pathways in all existing analysis
approaches. For instance, any ORA method will assign higher
significance (typically an order of magnitude lower p-value) to a
pathway with more genes. Similarly, more genes in a pathway also
increase the probability of a higher pathway-level statistic in FCS
approaches, yielding higher significance for a given pathway.
However, this contextual information is typically not available
from most of the existing knowledge bases. A standard functional
annotation format discussed above would make this information
available to curators and developers. For instance, the recently
proposed Biological Connection Markup Language (BCML)
allows pathway representation to specify the cell or organism in
which each pathway interaction occurs [62]. Furthermore, BCML
can generate cell-, condition-, or organism-specific pathways based
on user-defined query criteria, which in turn can be used for
targeted analysis.
Existing knowledge bases do not describe the effects of an
abnormal condition on a pathway (Figure 2). For example, it is not
clear how the Alzheimer’s disease pathway in KEGG differs from
a normal pathway (http://www.genome.jp/kegg/pathway/hsa/
hsa05010.html), nor it is clear which set of interactions leads to
Alzheimer’s disease. We are now beginning to understand that
context plays an important role in pathway interactions.
Information about how cell and tissue type, age, and environ-
mental exposures affect pathway interactions will add complexity
that is currently lacking.
Methodological Challenges
Benchmark data sets for comparing different
methods. Although multivariate pathway-level statistics
outperform univariate statistics on simulated data, univariate
statistics are equal to or better than multivariate statistics on real
biological data [1]. This fact raises a question of how to assess
performance of pathway analysis methods. One way to address the
question is to compare different methods against a set of
benchmark data sets.
Using simulated data [1,18] as a benchmark has the advantage
of comparing sensitivity and specificity of different methods.
However, biology is more complicated than simulated data.
Biological data are often affected by confounding factors such as
absence of a pure division into classes, presence of outliers,
experimental or technical ‘‘hidden’’ factors, etc. Therefore, it is
desirable to use real biological data as benchmark data sets.
A number of well-studied biological data sets can be used for
this purpose [21,29,63–65]. However, when using real biological
data, the actual biology is never fully known. Furthermore,
different definitions of the same pathway in different knowledge
bases can affect performance assessment in terms of power, and
the number of true positives and true negatives. For instance, GO
defines different pathways for apoptosis in different cells (e.g.,
cardiac muscle cell apoptosis, B cell apoptosis, T cell apoptosis). It
further distinguishes between induction and regulation of
apoptosis. Alternatively, KEGG defines a single signaling pathway
for apoptosis, and does not distinguish between induction and
regulation. Hence, an approach using KEGG would identify a
single pathway as significant, whereas GO could identify multiple
pathways, and/or specific aspects of a single apoptosis pathway.
Inability to model and analyze dynamic response. While
information missing from pathway knowledge bases limits analysis
from a systems biology perspective, no existing approach can
collectively model and analyze high-throughput data as a single
dynamic system. Current approaches are designed to analyze a
snapshot of a biological system by assuming that each pathway is
independent of the others at a given time. A typical approach for
analyzing dynamic response at the pathway level is to measure
expression changes at multiple time points, and analyze each time
point individually to see which pathways are significant at each
time point [66,67]. These approaches implicitly also assume that
pathways at different time points are independent of each other.
The lack of a model that accounts for dependence among
pathways at different time points limits our ability to observe
changes at a pathway level in a biological system.
For example, existing approaches for pathway analysis of gene
expression profiles obtained from transplanted organ biopsies on
day 1 would identify antigen processing and presentation pathway as
significant, but probably fail to identify other downstream
pathways, such as cytokine-cytokine receptor signaling and Tc e l lr e c e p t o r
signaling. This failure is due to the fact that existing approaches do
not account for inter-pathway dependence, such as activation of
antigen processing and presentation pathway leading to activation of
other immune pathways. The lack of methods that analyze
pathways as a dynamic system is, in part, due to limitations of
current molecular measurement technologies. These technologies
can only quantify a snapshot of a biological system because (i)
they are unable to determine protein states in a high-throughput
fashion or are severely restricted in this regard; and (ii) they are
unable to detect signals that propagate without affecting gene
expression.
Topology-based analysis approaches can potentially model and
analyze dynamic responses. For example, IF analysis models each
pathway as a linear system and propagates changes in gene
expression as perturbations in the system via interactions between
gene products [38–40,43]. However, these approaches also assume
that the expression levels of all genes, measured at a specific time
PLoS Computational Biology | www.ploscompbiol.org 7 February 2012 | Volume 8 | Issue 2 | e1002375point, are constant and never change. This assumption almost
never holds, as there are positive and negative feedback loops in
pathways that continuously regulate expression of different genes.
Furthermore, the assumptions made to propagate signals through
the biological system and estimate expression changes of the other
genes/proteins on each pathway are very gross, although they
have been shown to provide useful insights.
Inability to model effects of an external stimuli. Gene
set–based approaches often only consider genes and their
products, and completely ignore the effects of other molecules
participating in a pathway, such as the rate limiting step of a multi-
step pathway. For instance, the amount/strength of Ca
2+ causes
different transcription factors to be activated [68,69]. However,
this information is usually not available, due to lack of
experimental data, although efforts are being made to make
these types of data available in the public domain [70]. None of
the existing approaches fully incorporate this information in their
models, although PT-based analysis methods potentially have the
ability to consider some of them.
Conclusion
In the last decade, pathway analysis has become the first choice
for extracting and explaining the underlying biology for high-
throughput molecular measurements. Today, virtually every
bioinformatics study looks for statistically significant pathways as
either biological interpretation or validation of computationally
derived results. This paper discusses the evolution of pathway
analysis methods of high-throughput molecular measurements in
the last decade, distinctly divided into three generations based on
the type of analysis they performed. Although widely adopted, the
first generation of pathway analysis methods, ORA methods,
decouple molecular measurements from functional analysis and
assume that genes and pathways are independent of each other.
The second-generation FCS methods address these limitations.
PT-based methods further improve FCS methods by considering
the number and type of interactions between genes, which FCS
methods ignore.
However, despite these efforts, there are outstanding annotation
and methodological challenges. First, low resolution knowledge
bases, missing condition- and cell-specific information, and
incomplete annotations restrict development of the next-genera-
tion pathway analysis methods. Second, the inability to integrate
the dynamic nature of a biological system in analysis limits the
utility of existing methods. However, despite these hurdles, as the
number and type of functional annotations increase, coupled with
technological advances and analysis methods that provide better
guidance for strategic planning for subsequent biological experi-
ments, the utility of pathway analysis and confidence in results will
likely improve. The community must address these challenges
collectively to move pathway analysis into the next generation that
is able to utilize the new high-throughput technologies in order to
better understand large biological systems and to increase the
specificity, sensitivity, and relevance of pathway analysis, and
consequently, its utility.
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